Webinar
Do you have peptide drug candidates in development? Attend our webinar co-presented by Yen-Huei Lin, Ph.D. Exec. Director, Biopharmaceutical Development and Manufacturing at Neuraly and…
Do you have peptide drug candidates in development? Attend our webinar co-presented by Yen-Huei Lin, Ph.D. Exec. Director, Biopharmaceutical Development and Manufacturing at Neuraly and William Fang, Head of Oligo/Peptide Business at WuXi STA about how an integrated CMC partnership was critical in accelerating a novel peptide to phase 1 clinical trial.
Keep reading
Process mass intensity (PMI) is one of the most important metrics in sustainable manufacturing. It measures the total mass of raw materials required to produce a given mass of product. In…
As GLP-1 receptor agonists continue to redefine treatment for metabolic diseases, drug developers are racing to bring new and more complex therapies to the clinic. But innovation alone is…
A new publication by MSD in Organic Process Research & Development details the process development and large-scale manufacturing of the key Northern Fragment of Enlicitide Decanoate.
How can we help?
Tell us where your molecule is today — discovery, CMC, or commercial supply — and we will map the fastest credible route to patients.
Small molecule projects? WuXi STA